← Leaderboards
Gutian Xiao
Rutgers, The State Univ Of N.J.
$5,239,926
Attributed
$7,068,187
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,068,187 · 6
By mechanism
R01$6,302,684 · 4
R21$765,503 · 2
Top collaborators
- Zhaoxia Qu9 shared
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventMolecularProteinsPlayUbiquitin-Protein LigaseNuclearLim DomainLinkPathogenesisRepressionInnovationIn VitroCellsIn VivoTumorInvestigationLung TumorigenesisMalignant Neoplasm Of LungLungMalignant NeoplasmsTumor Suppressor ProteinsKnock-OutCessation Of LifeMediating
Grant awards (24)
Structural and molecular dissection of NF-kappaB regulation by the ubiquitin E3 ligase PDLIM2 in lung innate immunity and diseases$478,500
R01 · FY2025 · GM
Mechanistic difference of NF-kappaB in lung physiology and tumorigenesis$389,761
R01 · FY2025 · CA
Structural and molecular dissection of NF-kappaB regulation by the ubiquitin E3 ligase PDLIM2 in lung innate immunity and diseases$478,500
R01 · FY2024 · GM
Mechanistic difference of NF-kappaB in lung physiology and tumorigenesis$370,274
R01 · FY2024 · CA
Structural and molecular dissection of NF-kappaB regulation by the ubiquitin E3 ligase PDLIM2 in lung innate immunity and diseases$478,500
R01 · FY2023 · GM · contact PI
Mechanistic difference of NF-kappaB in lung physiology and tumorigenesis$381,967
R01 · FY2023 · CA · contact PI
Administrative Supplement: Dissection of NF-kappaB regulation by the ubiquitin E3 ligase PDLIM2 in lung innate immunity and diseases$210,759
R01 · FY2023 · GM · contact PI
Structural and molecular dissection of NF-kappaB regulation by the ubiquitin E3 ligase PDLIM2 in lung innate immunity and diseases$478,500
R01 · FY2022 · GM · contact PI
Mechanistic difference of NF-kappaB in lung physiology and tumorigenesis$389,761
R01 · FY2022 · CA · contact PI
Faithful Mouse Modeling of Human Lung Cancer$388,264
R21 · FY2021 · CA · contact PI
Faithful mouse modeling of human lung cancer$16,770
R21 · FY2021 · CA · contact PI
PDLIM2 as a cancer and chemosensitizing target$319,550
R01 · FY2017 · CA · contact PI
PDLIM2 as a cancer and chemosensitizing target$319,550
R01 · FY2016 · CA · contact PI
PDLIM2 as a cancer and chemosensitizing target$319,550
R01 · FY2015 · CA · contact PI
PDLIM2 as a cancer and chemosensitizing target$309,460
R01 · FY2014 · CA · contact PI
Modeling ETP-ALL in mouse$194,625
R21 · FY2014 · CA · contact PI
PDLIM2 as a cancer and chemosensitizing target$316,438
R01 · FY2013 · CA · contact PI
Modeling ETP-ALL in mouse$165,844
R21 · FY2013 · CA · contact PI
HTLV deregulation of NF-kappaB2 p100 processing in tumor$227,450
R01 · FY2010 · CA · contact PI
HTLV deregulation of NF-kappaB2 p100 processing in tumor$208,891
R01 · FY2009 · CA · contact PI
HTLV deregulation of NF-kappaB2 p100 processing in tumor$208,547
R01 · FY2008 · CA · contact PI
HTLV deregulation of NF-kappaB2 p100 processing in tumor$153,239
R01 · FY2007 · CA · contact PI
HTLV deregulation of NF-kappaB2 p100 processing in tumor$53,726
R01 · FY2007 · CA · contact PI
HTLV deregulation of NF-kappaB2 p100 processing in tumor$209,761
R01 · FY2006 · CA · contact PI